Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DCJX65
|
|||
Drug Name |
UNC2025
|
|||
Synonyms |
1429881-91-3; UNC-2025; mrx-6313; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol; CHEMBL3326006; 4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol; UNC2025A; SCHEMBL14854194; SCHEMBL15978986; SCHEMBL21797957; BDBM350845; BCP16544; EX-A1030; BDBM50055496; MFCD28142874; s9662; AKOS025289796; ZINC210464182; ZINC249857461; CS-3354; SB16838; NCGC00390618-01; NCGC00482875-01; AK171371; AS-52179; DA-44845; HY-12344; US9795606, B4; B8016; FT-0743029; (1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 2109176-09-0; 4-(2-(Butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexan-1-ol; 4beta-[2-(Butylamino)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidine-7-yl]cyclohexane-1alpha-ol; R6N
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Glioblastoma of brain [ICD-11: 2A00.00; ICD-10: C71] | Investigative | [1] | |
Company |
University of North Carolina
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H40N6O
|
|||
Canonical SMILES |
CCCCNC1=NC=C2C(=CN(C2=N1)C3CCC(CC3)O)C4=CC=C(C=C4)CN5CCN(CC5)C
|
|||
InChI |
1S/C28H40N6O/c1-3-4-13-29-28-30-18-25-26(20-34(27(25)31-28)23-9-11-24(35)12-10-23)22-7-5-21(6-8-22)19-33-16-14-32(2)15-17-33/h5-8,18,20,23-24,35H,3-4,9-17,19H2,1-2H3,(H,29,30,31)
|
|||
InChIKey |
MJSHVHLADKXCML-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tyrosine-protein kinase Mer (MERTK) | Target Info | Inhibitor | [1] |
NetPath Pathway | TSH Signaling Pathway | |||
Reactome | Cell surface interactions at the vascular wall | |||
WikiPathways | Cell surface interactions at the vascular wall |
References | Top | |||
---|---|---|---|---|
REF 1 | MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.